Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 7/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324273 | 0.94 | PDE4B (0.39) | PDE4BPDE4APDE4DHRH3KDM5A | |
| SCHEMBL4191409 | 0.90 | PDE4B (0.50) | PDE4BPDE4APDE4DCNR2CNR1 | |
| SCHEMBL4180093 | 0.88 | PDE4B (0.41) | PDE4BPDE4APDE4DCNR2CNR1 | |
| SCHEMBL4191504 | 0.88 | PDE4B (0.42) | PDE4BPDE4APDE4DCNR2CNR1 | |
| SCHEMBL13929015 | 0.87 | KDM5A (0.41) | PDE4BPDE4APDE4DKDM5ACNR2 | |
| SCHEMBL4189964 | 0.87 | KDM5A (0.41) | PDE4BPDE4APDE4DKDM5ACNR2 | |
| SCHEMBL4185131 | 0.86 | PDE4B (0.41) | PDE4BPDE4APDE4DCNR2CNR1 | |
| SCHEMBL4191242 | 0.85 | PDE4B (0.49) | PDE4BPDE4APDE4DCNR2CNR1 | |
| SCHEMBL13929017 | 0.85 | PDE4B (0.50) | PDE4BPDE4APDE4DCNR2CNR1 | |
| SCHEMBL4187186 | 0.83 | PDE4B (0.44) | PDE4BPDE4APDE4DCNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | claimed |
| US-20050020611-A1 | Compounds | PFIZER INC. | 2005-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020611-A1 | Compounds | NQO1, NAMPT, NNT | PDE4B 719/4885PDE4A 1024/4885PDE4D 1102/4885 |
| US-20090035313-A1 | Compounds | NQO1, NAMPT, NNT | PDE4B 719/4885PDE4A 1024/4885PDE4D 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.